Background Familial hypercholesterolemia (FH) is a codominant autosomal disease characterized by high low-density lipoprotein cholesterol (LDLc) and a high risk of premature cardiovascular disease (CVD). The molecular bases have been well defined, and effective lipid lowering is possible. This analysis aimed to study the current major causes of death of genetically defined heterozygous familial hypercholesterolemia (heFH). Methods A case‒control study was designed to analyse life-long mortality in a group of heFH and control families. Data from first-degree family members of cases and controls (nonconsanguineous cohabitants), including deceased relatives, were collected from a questionnaire and review of medical records. Mortality was comp...
This editorial refers to ‘Prediction of cardiovascular risk in patients with familial hypercholeste...
AbstractBackgroundSome recently emerged lipid-lowering therapies are currently restricted to patient...
amilial hypercholesterolaemia (FH) is a monogenic disorder of low-density lipoprotein (LDL) metaboli...
Background Familial hypercholesterolemia (FH) is a codominant autosomal disease characterized by hig...
Background and aims: Familial hypercholesterolemia (FH) is a metabolic autosomal dominant disorder. ...
Familial hypercholesterolemia (FH) is a common genetic cause of premature cardiovascular disease (CV...
Familial hypercholesterolemia (FH) is a common genetic cause of elevated low-density lipoprotein cho...
Clinical management of heterozygous familial hypercholesterolaemia is largely based on evidence from...
Cardiovascular disease (CVD) remains the most common cause of death globally. Dyslipidaemia is one o...
International audienceBackground and aims: Heterozygous familial hypercholesterolemia (HeFH) is incr...
Familial Hypercholesterolaemia (FH) is the commonest autosomal co-dominantly inherited condition af...
In recent studies, the reported prevalence of heterozygous familial hypercholesterolemia (FH) has be...
textabstractFamilial hypercholesterolemia (FH) (OMIM #143890) is an autosomal dominant disorder pres...
Background and aims There is a paucity of data concerning the influence of lipid-lowering therapy on...
and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: ...
This editorial refers to ‘Prediction of cardiovascular risk in patients with familial hypercholeste...
AbstractBackgroundSome recently emerged lipid-lowering therapies are currently restricted to patient...
amilial hypercholesterolaemia (FH) is a monogenic disorder of low-density lipoprotein (LDL) metaboli...
Background Familial hypercholesterolemia (FH) is a codominant autosomal disease characterized by hig...
Background and aims: Familial hypercholesterolemia (FH) is a metabolic autosomal dominant disorder. ...
Familial hypercholesterolemia (FH) is a common genetic cause of premature cardiovascular disease (CV...
Familial hypercholesterolemia (FH) is a common genetic cause of elevated low-density lipoprotein cho...
Clinical management of heterozygous familial hypercholesterolaemia is largely based on evidence from...
Cardiovascular disease (CVD) remains the most common cause of death globally. Dyslipidaemia is one o...
International audienceBackground and aims: Heterozygous familial hypercholesterolemia (HeFH) is incr...
Familial Hypercholesterolaemia (FH) is the commonest autosomal co-dominantly inherited condition af...
In recent studies, the reported prevalence of heterozygous familial hypercholesterolemia (FH) has be...
textabstractFamilial hypercholesterolemia (FH) (OMIM #143890) is an autosomal dominant disorder pres...
Background and aims There is a paucity of data concerning the influence of lipid-lowering therapy on...
and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: ...
This editorial refers to ‘Prediction of cardiovascular risk in patients with familial hypercholeste...
AbstractBackgroundSome recently emerged lipid-lowering therapies are currently restricted to patient...
amilial hypercholesterolaemia (FH) is a monogenic disorder of low-density lipoprotein (LDL) metaboli...